# Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

> **NCT03710772** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 51 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Dexamethasone
- **DRUG:** Doxorubicin Hydrochloride
- **DRUG:** Ibrutinib
- **DRUG:** Methotrexate
- **BIOLOGICAL:** Rituximab
- **DRUG:** Venetoclax
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT03710772
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-01
- **Primary completion:** 2027-03-22
- **Final completion:** 2027-03-22
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03710772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03710772, "Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03710772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*